Status:

UNKNOWN

Empagliflozin to Prevent Post-Operative Atrial Fibrillation

Lead Sponsor:

Rajaie Cardiovascular Medical and Research Center

Collaborating Sponsors:

Tehran Heart Center

Conditions:

Post-operative Atrial Fibrillation

CABG

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication. The goal of present study is...

Detailed Description

Study aim: Evaluating the role of empagliflozin on the rate of postoperative atrial fibrillation in comparison with placebo Design: Two arms, parallel-group, phase 3, randomized, double-blind, placebo...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Adult patients (≥18 years) who are candidates for isolated CABG
  • Patients who provided written informed consent and are willing to participate in the study
  • Exclusion criteria
  • History of type Ⅰ or Ⅱ diabetes mellitus
  • History of ketoacidosis
  • History of atrial fibrillation or flutter
  • History of recurrent UTI
  • SGLT2I or any other oral hypoglycemic medications used due to other indications
  • Patients with acute kidney injury (45)
  • Severe hepatic disease (Child-Pugh score C)
  • Patients with Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m2
  • Patients who are candidates for emergent CABG
  • Patients with unstable hemodynamic state
  • Patients with positive urine culture, urinary symptoms (frequency, dysuria, hesitancy), and asymptomatic bacteriuria
  • Patients who are enrolled in other clinical trials
  • Patients with a history of drug-sensitive reactions to SGLT2I
  • Pregnancy or lactation

Exclusion

    Key Trial Info

    Start Date :

    November 7 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 30 2024

    Estimated Enrollment :

    492 Patients enrolled

    Trial Details

    Trial ID

    NCT06124937

    Start Date

    November 7 2023

    End Date

    December 30 2024

    Last Update

    November 22 2023

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Tehran Heart Center

    Tehran, Iran, 1411713138

    2

    Rajaie Cardiovascular Medical & Research Center

    Tehran, Iran, 1995614331

    Empagliflozin to Prevent Post-Operative Atrial Fibrillation | DecenTrialz